Results 221 to 230 of about 151,397 (266)

Denosumab Offers Relatively Lower Initial Protection Against Osteoporotic Vertebral Fractures in Treatment‐Naive Patients Compared With Zoledronate

open access: yesClinical Pharmacology &Therapeutics, EarlyView.
We compared the initial efficacy of denosumab (Dmab) and zoledronate (ZOL) in treatment‐naive patients with osteoporosis. This cohort study, based on TriNetX data, evaluated the risks of fractures and mortality using Kaplan–Meier survival analyses, with hazard ratios (HRs) and 95% confidence intervals (CIs).
Ko‐Hsiu Lu   +2 more
wiley   +1 more source

Achieving Fairness Without Harm via Selective Demographic Experts. [PDF]

open access: yesProc AAAI Conf Artif Intell
Tan X   +4 more
europepmc   +1 more source

Cardiorenal Outcomes of Dapagliflozin vs. Empagliflozin in Advanced Chronic Kidney Disease and Diabetes

open access: yesClinical Pharmacology &Therapeutics, EarlyView.
Target trial emulation of a multi‐institutional electronic health record network showed comparable cardiorenal effectiveness and safety of dapagliflozin versus empagliflozin in adults with type 2 diabetes and advanced‐stage chronic kidney disease.
Shih‐Hsuan Lin   +6 more
wiley   +1 more source

A General Group Testing Strategy for Discovering Chemical Cooperativity. [PDF]

open access: yesAngew Chem Int Ed Engl
Pflüger PM   +9 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy